Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+B-Lineage Standard and High Risk Patients; Results of 263 CD20+Patients Studied Prospectively In GMALL Study 07/2003

被引：62

作者：

Hoelzer, Dieter ^{[1
]}

Huettmann, Andreas ^{[2
]}

Kaul, Felix ^{[3
]}

Irmer, Sebastian ^{[4
]}

Jaekel, Nadja ^{[5
]}

Mohren, Martin ^{[6
]}

Lipp, Thomas ^{[7
]}

Wedelin, Knut ^{[8
]}

de Valle, Francisco ^{[9
]}

Schmid, Mathias ^{[10
]}

Thiel, Eckhard ^{[11
]}

Brueggemann, Monika ^{[4
]}

Kneba, Michael ^{[12
]}

Goekbuget, Nicola ^{[13
]}

机构：

[1] Goethe Univ Frankfurt, Frankfurt, Germany

[2] Univ Hosp, Essen, Germany

[3] Univ Hosp, Freiburg, Germany

[4] Univ Hosp Kiel, Kiel, Germany

[5] Univ Hosp Leipzig, Leipzig, Germany

[6] Univ Hosp Magdeburg, Magdeburg, Germany

[7] Krankenhaus Munchen Schwabing, Munich, Germany

[8] Klinikum Nuernberg Nord Nurnberg, Nurnberg, Germany

[9] Klin Onkol & Hamatol, Oldenburg, Germany

[10] Univ Ulm, Ulm, Germany

[11] Charite, Charite Ctr 14, Med Klin Hamatol Onkol & Transfus Med 3, D-13353 Berlin, Germany

[12] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[13] JW Goethe Univ Hosp, Dept Med 2, Frankfurt, Germany

来源：

关键词：

D O I：

10.1182/blood.V116.21.170.170

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：77 / 78

页数：2